AbCheck licenses mAB technology
Enlarge image

BusinessCzech Republic

AbCheck licenses mAB technology

14.11.2012 - Plzen-based AbCheck s.r.o.has licensed an affinity maturation and antibody optimisation platform from US bioinformatics company Distributed Bio LCC.

Under the terms of the exclusive, worldwide agreement, AbCheck will apply Distributed Bio LCC’s proprietary computational library design algorithms to address the affinity maturation, therapeutic 'developability' and stability optimisation of antibodies in a one-step process.  According to the Czech antibody specialist, the platform of the US bioinformatics specialist makes it possible to deliver functional, "GMP ready", antibodies with significantly increased affinities with minimal mutations from fully human frameworks from its phage and yeast display antibody libraries

AbCheck CEO Volker Lang stressed: "By combining the strength of both technologies we have created a platform that exactly addresses current market needs.“ "Library design algorithms redefine the full potential of high throughput screening," said Jacob Glanville, Scientific Director of Distributed Bio. "Distributed Bio's library design algorithms encode years of protein engineering directly into the library designs. We are delighted to bring this technology forward with AbCheck: their leading edge expertise in antibody engineering and library development make them an ideal partner for introducing this new technology to the market.

Abcheck uses its AbSieve platform to develop antibodies for partners in all antibody formats, and its AbAccel algorithm for affinity maturation and optimisation. Distributed Bio provides antibody informatics, including: sequence & structural analysis; affinity maturation & humanisation; NextGen repertoire sequencing; phage display panning and library analysis.



24.11.2015 After weeks of speculation it is official: US pharma major Pfizer and Irish Botox maker Allergan will merge. With the deal, Pfizer is planning to dodge the high US taxes, causing indignation among US politicians.


23.11.2015 Amidst talk of the IPO window closing and cancelled flotations, diagnostics firms are still striking a chord with investors. Swedish Immunovia and German Curetis are successfully raising public money.


20.11.2015 French Sanofi and British AstraZeneca are giving open innovation a go: The two pharma giants will exchange thousands of compounds – for free.


19.11.2015 French gene editing company Cellectis has granted Servier the rights to bring cancer immunotherapy UCART19 to market. Servier in turn has teamed up with Pfizer to hurry development along.


17.11.2015 The first Italian accelerator specifically for biotech projects has been launched with help from Sofinnova Partners. The plan of BiovelocITA: to help Italy grow into one of Europe’s strongest biotech markets.


13.11.2015 Scientists in Bath, UK, have developed a medical dressing that turns fluorescent green when it detects infection. The researchers hope that the smart burns dressing will help fight antibiotic resistance.


13.11.2015 Out with the old: Roche is discarding four sites with 1,200 staff in an effort to restructure its manufacturing network for small molecules. Instead, a new manufacturing site will be built in Switzerland.


10.11.2015 Algae have many skills, but cancer fighting was not one of them – until now. Researchers from Australia and Germany have genetically engineered diatom algae to accurately deliver chemotherapeutic drugs.


10.11.2015 AstraZeneca has plucked Californian biopharma company ZS Pharma from under Actelion’s nose. The UK company is paying US$2.7bn (€2.5bn) to acquire ZS and its promising hyperkalaemia treatment currently under US regulatory review.


04.11.2015 What biotech stock market slump? Despite all odds, 2015 is set to become a new record year for the European public biotech sector, according to a BIOCOM-study presented at BIO Europe in Munich.


All Events


Strasbourg (F)

BioFIT 2015

Current issue

All issues

Product of the week


Stock list

All quotes


  • THERAMETRICS (CH)0.05 CHF25.00%
  • MOLOGEN (D)4.10 EUR13.89%


  • DIAMYD MEDICAL -B- (S)8.75 SEK-5.91%
  • IMMUNICUM AB (S)40.60 SEK-5.80%
  • CELLECTIS (F)29.57 EUR-5.07%


  • PLETHORA (UK)5.50 GBP76.3%
  • PROTHENA PLC (IE)73.20 USD46.1%
  • CELLECTIS (F)29.57 EUR27.9%


  • EPIGENOMICS (D)1.84 EUR-59.3%
  • EVOCUTIS (UK)0.10 GBP-33.3%


  • KARO BIO (S)37.50 SEK5181.7%
  • CHRONTECH PHARMA (S)0.34 SEK1600.0%
  • GALAPAGOS (B)44.82 EUR249.1%


  • BIOTEST (D)15.03 EUR-81.4%
  • NEOVACS (F)0.72 EUR-79.1%

No liability assumed, Date: 25.11.2015